Related Experiment Video
Updated: Jun 4, 2026
11:16
A Novel Procedure for Evaluating the Reinforcing Properties of Tastants in Laboratory Rats: Operant Intraoral Self-administration
Published on: February 6, 2014
[Drug control of appetite]
1Service d'enseignement thérapeutique pour maladies chroniques, Centre collaborateur de l'OMS, Département de médecine communautaire, de premier recours et des urgences, HUG, 1211 Genève 14. vincent.makoundou@hcuge.ch
Revue Medicale Suisse
|February 12, 2011
Summary
New obesity drugs offer fewer side effects by targeting specific receptors or using novel mechanisms like GLP-1 and leptin. Combination therapies show promise, but appetite dysregulation requires further research.
Area of Science:
- Pharmacology
- Neuroendocrinology
- Obesity Research
Context:
- Obesity management relies on appetite control, a complex neurohormonal process.
- Previous appetite-regulating drugs faced withdrawal due to severe side effects.
- Emerging research focuses on novel pharmacological agents with improved safety profiles.
Purpose:
- To review current advancements in drug development for appetite control in obesity management.
- To highlight new substances with enhanced receptor specificity or novel mechanisms of action.
- To discuss the potential of combination therapies (polypills) in addressing appetite dysregulation.
Summary:
- Drug development for appetite control is evolving, moving beyond older medications with significant side effects.
- New agents like locarserin (receptor specificity) and GLP-1 agonists, leptin, and anti-ghrelin therapies (novel mechanisms) are being developed.
- Combination therapies, such as naltrexone-bupropion and phentermine-topiramate, demonstrate encouraging outcomes.
Impact:
- Advances in understanding appetite regulation are paving the way for safer and more effective obesity treatments.
- Targeted drug development offers hope for improved patient outcomes in obesity management.
- Further research into the dominant mechanisms of appetite dysregulation is crucial for future therapeutic strategies.
Related Concept Videos
01:30Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
01:15Drug Abuse and Addiction: Pharmacological Phenomena
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...
01:17Drug Dependence
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...